IN2014MN01795A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01795A
IN2014MN01795A IN1795MUN2014A IN2014MN01795A IN 2014MN01795 A IN2014MN01795 A IN 2014MN01795A IN 1795MUN2014 A IN1795MUN2014 A IN 1795MUN2014A IN 2014MN01795 A IN2014MN01795 A IN 2014MN01795A
Authority
IN
India
Prior art keywords
patient
biological fluid
percentage
bcl2l10 protein
sample
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas Cluzeau
Patrick Auberger
Guillaume Robert
Frédéric Luciano
Original Assignee
Université Nice Sophia Antipolis
Ct Hospitalier Universitaire Nice
Inst Nat Santé Et De La Rech Médicale Inserm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Nice Sophia Antipolis, Ct Hospitalier Universitaire Nice, Inst Nat Santé Et De La Rech Médicale Inserm filed Critical Université Nice Sophia Antipolis
Publication of IN2014MN01795A publication Critical patent/IN2014MN01795A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/57575—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/57505—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1795MUN2014 2012-02-28 2013-02-28 IN2014MN01795A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1200584A FR2987446B1 (fr) 2012-02-28 2012-02-28 Test diagnostic de la resistance a l'azacitidine
PCT/FR2013/000055 WO2013128089A1 (fr) 2012-02-28 2013-02-28 Test diagnostic de la résistance à l'azacitidine

Publications (1)

Publication Number Publication Date
IN2014MN01795A true IN2014MN01795A (de) 2015-07-03

Family

ID=48083449

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1795MUN2014 IN2014MN01795A (de) 2012-02-28 2013-02-28

Country Status (11)

Country Link
US (1) US20150094217A1 (de)
EP (1) EP2820417A1 (de)
JP (1) JP6273552B2 (de)
CN (1) CN104321649A (de)
AU (1) AU2013224832A1 (de)
BR (1) BR112014021173A2 (de)
CA (1) CA2865684A1 (de)
FR (1) FR2987446B1 (de)
IL (1) IL234332A0 (de)
IN (1) IN2014MN01795A (de)
WO (1) WO2013128089A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042650B1 (de) * 2014-03-27 2020-06-10 Palacky University, Olomouc Bromdomänenhemmer jq1 in kombination mit dna-methylierungshemmer dac zur verwendung bei der krebsbehandlung
FR3048698B1 (fr) * 2016-03-11 2021-03-05 Univ Claude Bernard Lyon Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
WO2019077080A1 (en) * 2017-10-19 2019-04-25 Universite Claude Bernard Lyon 1 ASSESSING THE RISK OF METASTATIC RECHUTE IN PATIENTS WITH BREAST CANCER
CN114874987A (zh) * 2022-03-01 2022-08-09 洛阳市中心医院（郑州大学附属洛阳中心医院） 一种骨髓异常增生综合征耐药细胞模型及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143236A1 (en) 2004-02-13 2009-06-04 Bml, Inc. Method of detecting cancer cell acquiring drug-resistance
EP2163650B1 (de) * 2004-04-09 2015-08-05 Genomic Health, Inc. Genexpressionsmarker zur Vorhersage des Erfolgs von Chemotherapy
WO2010045651A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc. Methods for analyzing drug response
CN101632643A (zh) * 2009-08-18 2010-01-27 杭州咸达医药科技有限公司 阿扎胞苷冻干粉针制剂及其制备方法
JP5190477B2 (ja) * 2010-02-22 2013-04-24 譲治 稲澤 カンプトテシン類の制癌剤に対する薬剤耐性を獲得した肺癌細胞の検出方法
PT2576825T (pt) * 2010-05-27 2018-02-02 Inst Nat Sante Rech Med Métodos para avaliar a receptividade do endométrio de uma doente

Also Published As

Publication number Publication date
CA2865684A1 (fr) 2013-09-06
US20150094217A1 (en) 2015-04-02
FR2987446A1 (fr) 2013-08-30
AU2013224832A1 (en) 2014-10-16
CN104321649A (zh) 2015-01-28
FR2987446B1 (fr) 2016-01-01
AU2013224832A8 (en) 2014-11-13
BR112014021173A2 (pt) 2017-08-22
IL234332A0 (en) 2014-10-30
JP2015513369A (ja) 2015-05-11
JP6273552B2 (ja) 2018-02-07
EP2820417A1 (de) 2015-01-07
WO2013128089A1 (fr) 2013-09-06

Similar Documents

Publication Publication Date Title
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
EA201590247A1 (ru) Антитела к siglec-15
SG10201903822XA (en) Method for the enrichment of circulating tumor dna
ZA201604468B (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
IL246060A0 (en) Biosensors for biological or chemical analysis and methods for their production
PL2986735T3 (pl) Sposób określania składu ilościowego komórek krwi w próbce
PH12013500544A1 (en) Breast cancer diagnostics
WO2012122564A3 (en) Diagnostic and sample preparation devices and methods
WO2012094580A3 (en) Compounds that modulate oxidative stress
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
MX2022013625A (es) Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.
ZA201402460B (en) Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly
PT3155421T (pt) Recipiente para determinar analitos e/ou parâmetros físicoquímicos, bem como para determinar o sedimento urinário na urina, e método de análise completa da urina utilizando este recipiente
HK1254030A1 (zh) 治疗自身免疫病症和同种免疫病症的方法
MX358997B (es) Metodo para evaluar la reaccion de coagulacion sanguinea.
EP2909589A4 (de) Vorrichtung und verfahren zur ultraschallanalyse biologischer proben
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
IN2014MN01795A (de)
SG11201700876RA (en) Methods and compositions for analyzing glucose-6-phosphate dehydrogenase activity in blood samples
MX2019008005A (es) Metodos y composiciones para diagnosticar preeclampsia.
WO2012131092A3 (en) Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages
WO2012144784A3 (ko) 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
WO2011141153A8 (en) Methods for the diagnosis and prognosis of a tumor using bcat1 protein
WO2014198670A3 (en) Methods of viewing and analyzing high content biological data